AKT1 and glioblastoma: The results showed that cell proliferation and EGFR-AKT signaling pathway activity were significantly inhibited in the circSPECC1 overexpression combined with TMZ treatment group, and circSPECC1 overexpression restored the sensitivity of TMZ-resistant GBM to TMZ (Fig. 9D).